Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.1849
+0.0069 (3.88%)
At close: Apr 1, 2025, 4:00 PM
0.1780
-0.0069 (-3.73%)
After-hours: Apr 1, 2025, 4:37 PM EDT
Company Description
Ernexa Therapeutics Inc., a life science company, provides mRNA cell engineering technologies.
Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system.
It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Sanjeev Luther |
Contact Details
Address: 1035 Cambridge Street, Suite 18A Cambridge, Massachusetts 02141 United States | |
| Phone | 212 582 1199 |
| Website | eternatx.com |
Stock Details
| Ticker Symbol | ERNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000748592 |
| CUSIP Number | 114082209 |
| ISIN Number | US1140822099 |
| Employer ID | 31-1103425 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President and Director |
| Sandra M. Gurrola | Principal Financial and Accounting Officer and Senior Vice President of Finance |
| Dorothy J. Clarke | General Counsel |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |
| Mar 12, 2025 | 8-K | Current Report |
| Mar 5, 2025 | SCHEDULE 13D/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 28, 2025 | SCHEDULE 13G/A | Filing |